Passage Bio Ownership

PASG Stock  USD 8.52  0.46  5.12%   
The market capitalization of Passage Bio is $27.08 Million. Over half of Passage Bio's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.

Passage Stock Ownership Analysis

About 52.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.92. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Passage Bio recorded a loss per share of 14.62. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 14th of July 2025. Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. To find out more about Passage Bio contact William MD at 267 866 0311 or learn more at https://www.passagebio.com.

Passage Bio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Passage Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Passage Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Passage Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Kathleen Borthwick over a month ago
Disposition of 30000 shares by Kathleen Borthwick of Passage Bio subject to Rule 16b-3
 
Lynx1 Capital Management Lp over two months ago
Acquisition by Lynx1 Capital Management Lp of 19783 shares of Passage Bio at 6.9908 subject to Rule 16b-3
 
Lynx1 Capital Management Lp over two months ago
Acquisition by Lynx1 Capital Management Lp of 325 shares of Passage Bio at 6.9558 subject to Rule 16b-3
 
Lynx1 Capital Management Lp over three months ago
Acquisition by Lynx1 Capital Management Lp of 66423 shares of Passage Bio at 5.7127 subject to Rule 16b-3
 
Lynx1 Capital Management Lp over three months ago
Acquisition by Lynx1 Capital Management Lp of 13123 shares of Passage Bio at 5.4361 subject to Rule 16b-3
 
Orbimed Advisors Llc over three months ago
Disposition of 213257 shares by Orbimed Advisors Llc of Passage Bio at 0.33 subject to Rule 16b-3
 
Kassberg Thomas Richard over three months ago
Acquisition by Kassberg Thomas Richard of 143789 shares of Passage Bio at 0.3598 subject to Rule 16b-3
 
Orbimed Advisors Llc over six months ago
Disposition of 68195 shares by Orbimed Advisors Llc of Passage Bio at 0.32 subject to Rule 16b-3
 
Orbimed Advisors Llc over six months ago
Disposition of 89328 shares by Orbimed Advisors Llc of Passage Bio at 0.34 subject to Rule 16b-3
 
Orbimed Advisors Llc over six months ago
Disposition of 78049 shares by Orbimed Advisors Llc of Passage Bio at 0.34 subject to Rule 16b-3
 
Orbimed Advisors Llc over six months ago
Disposition of 77090 shares by Orbimed Advisors Llc of Passage Bio at 0.33 subject to Rule 16b-3
 
Orbimed Advisors Llc over six months ago
Disposition of 61638 shares by Orbimed Advisors Llc of Passage Bio at 0.33 subject to Rule 16b-3

Passage Bio Outstanding Bonds

Passage Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Passage Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Passage bonds can be classified according to their maturity, which is the date when Passage Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Currently Active Assets on Macroaxis

When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Passage Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.